21
Participants
Start Date
April 19, 2019
Primary Completion Date
December 21, 2021
Study Completion Date
March 22, 2022
Sotatercept
Sotatercept injection
SOC
SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
University of Pittsburgh Medical Center, Pittsburgh
Mayo Clinic, Rochester
The University of Arizona, Tucson
Brigham and Women's Hospital, Boston
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
INDUSTRY